$12.30 -$2.07 (-14.4%)

04:30 PM EDT on 08/04/20

Epizyme (NASDAQ:EPZM)

CAPS Rating: 2 out of 5

Current Price $12.30 Mkt Cap $1.4B
Open $14.17 P/E Ratio 0.00
Prev. Close $14.37 Div. (Yield) $0.00 (0.0%)
Daily Range $12.29 - $14.37 Volume 3,189,494
52-Wk Range $9.74 - $27.82 Avg. Daily Vol. 1,457,874

Caps

How do you think NASDAQ:EPZM will perform against the market?

Add Stock to CAPS Watchlist

All Players

36 Outperform
7 Underperform
 

All-Star Players

13 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:EPZM Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFEBCapital (97.56)
Submitted May 04, 2017

The company's making progress on developing drugs that interfere with gene expression, and results for its lead drug, tazemetostat, appear strong. It's being evaluated for use in molecularly defined solid tumors and non-Hodgkin lymphoma, and it's… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:EPZM VS S&P 500 (SPY)

Fools bullish on NASDAQ:EPZM are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about EPZM.

Recs

0
Member Avatar ak1010 (99.93) Submitted: 7/6/2020 5:15:35 PM : Outperform Start Price: $18.53 NASDAQ:EPZM Score: -33.18

?

Recs

0
Member Avatar Bigsef77 (70.02) Submitted: 1/4/2019 10:19:14 AM : Outperform Start Price: $9.87 NASDAQ:EPZM Score: -45.08

Epizyme on go with tazemetostat NDA in Q4
Jan. 4, 2019 7:08 AM ET|About: Epizyme (EPZM)|By: Douglas W. House, SA News Editor

Epizyme (NASDAQ:EPZM) announces that, based on FDA feedback, it expects to file its U.S. marketing application for tazemetostat for EZH2 mutation-positive and wild-type relapsed/refractory follicular lymphoma (FL) in Q4. Data from the ongoing Phase 2 study will support the application.

Recs

0
Member Avatar LazyHarlequin (95.17) Submitted: 8/2/2018 11:48:55 AM : Underperform Start Price: $9.00 NASDAQ:EPZM Score: -26.57

On 8/2/18 down $4.07 to $8.92. Options available for 2/15/19 with strike of $7.50.

Leaderboard

Find the members with the highest scoring picks in EPZM.

Score Leader

chris293

chris293 (30.88) Score: +164.87

The Score Leader is the player with the highest score across all their picks in EPZM.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
chris293 30.88 10/9/2013 Underperform 5Y $37.89 -65.80% +99.07% +164.87 1 Comment
ACMGresearch 34.19 6/3/2013 Underperform 5Y $25.04 -48.24% +102.70% +150.94 0 Comment
kevrose31 79.24 1/10/2014 Underperform 1Y $37.00 -64.97% +79.43% +144.40 0 Comment
jeepdrew2 21.55 12/5/2014 Underperform 5Y $21.76 -40.44% +58.78% +99.22 0 Comment
Corona20 34.14 3/12/2020 Underperform 5Y $16.63 -22.07% +30.74% +52.81 0 Comment
Playa14 < 20 10/17/2019 Outperform 5Y $10.42 +24.38% +10.50% +13.88 0 Comment
WarCapital 56.95 9/10/2018 Outperform 5Y $10.15 +27.68% +14.31% +13.37 0 Comment
tempttempt 69.64 7/18/2019 Outperform 5Y $12.93 +0.23% +11.06% -10.83 0 Comment
Novavm 99.12 8/3/2018 Underperform 5Y $9.90 +30.91% +16.82% -14.09 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. getrichdietrying 86.37 9/23/2016 Outperform 5Y $9.73 +33.20% +52.30% -19.10 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EPZM.